Pasar al contenido principal

INTERACCION FISIOPATOLOGICA ENTRE OBESIDAD Y LA GLANDULA PROSTATICA: INFLUENCIA DEL TEJIDO ADIPOSO EN LAS MAQUINARIAS DE CONTROL DE LA EXPRESION GENICA Y ESTABILIDAD GENOMICA

PID2019-105564RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE CORDOBA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes

  • Jiménez-Vacas, Juan M.
  • Montero-Hidalgo, Antonio J.
  • Gómez-Gómez, Enrique
  • Sáez-Martínez, Prudencio
  • Fuentes-Fayos, Antonio C.
  • Closa, Adrià
  • González-Serrano, Teresa
  • Martínez-López, Ana
  • Sánchez-Sánchez, Rafael
  • López-Casas, Pedro P.
  • Sarmento-Cabral, André
  • Olmos, David
  • Eyras Jiménez, Eduardo
  • Castaño, Justo P.
  • Gahete, Manuel D.
  • Luque, Raul M.
Prostate cancer (PCa) is one of the leading causes of cancer-related deaths among men. Consequently, the identification of novel molecular targets for treatment is urgently needed to improve patients' outcomes. Our group recently reported that some elements of the cellular machinery controlling alternative-splicing might be useful as potential novel therapeutic tools against advanced PCa. However, the presence and functional role of RBM22, a key spliceosome component, in PCa remains unknown. Therefore, RBM22 levels were firstly interrogated in 3 human cohorts and 2 preclinical mouse models (TRAMP/Pbsn-Myc). Results were validated in in silico using 2 additional cohorts. Then, functional effects in response to RBM22 overexpression (proliferation, migration, tumorspheres/colonies formation) were tested in PCa models in vitro (LNCaP, 22Rv1, and PC-3 cell-lines) and in vivo (xenograft). High throughput methods (ie, RNA-seq, nCounter PanCancer Pathways Panel) were performed in RBM22 overexpressing cells and xenograft tumors. We found that RBM22 levels were down-regulated (mRNA and protein) in PCa samples, and were inversely associated with key clinical aggressiveness features. Consistently, a gradual reduction of RBM22 from non-tumor to poorly differentiated PCa samples was observed in transgenic models (TRAMP/Pbsn-Myc). Notably, RBM22 overexpression decreased aggressiveness features in vitro, and in vivo. These actions were associated with the splicing dysregulation of numerous genes and to the downregulation of critical upstream regulators of cell-cycle (i.e., CDK1/CCND1/EPAS1). Altogether, our data demonstrate that RBM22 plays a critical pathophysiological role in PCa and invites to suggest that targeting negative regulators of RBM22 expression/activity could represent a novel therapeutic strategy to tackle this disease., This research was funded by the Spanish Ministry of Science, Innovation, and Universities (Research‐Grant: PID2019‐105564RB‐I00; Predoctoral contracts: FPU16/05059, FPU17/00263, FPU18/02485), Health Institute Carlos III (DTS20-00050), Junta de Andalucia [BIO-0139; Consejería de Transformación Económica, Industria, Conocimiento y Universidades (P20_00442); Consejería de Salud y Familias, co-funded by European Union (Programa Operativo FEDER de Andalucía 2014-2020, “Andalucía se mueve con Europa”: PEER-0048-2020)], and CIBERobn (CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain). Funding for open access charge: University of Córdoba/CBUA. Some images were taken from Servier Medical Art (smart.servier.com) under the Creative Commons Attribution 3.0 Unported License. Special thanks to the staff of Biobank of the IMIBIC and of the experimental animal service (SAE) of the UCO/IMIBIC. We are gratefully indented to all the patients and their families for generously donating the samples and clinical data for research purposes. All authors have read the journal's authorship agreement.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Decompressive hemicraniectomy without evacuation of acute intraparenchymal hemorrhage

  • Blanco-Acevedo, Cristóbal
  • Aguera-Morales, Eduardo
  • Fuentes-Fayos, Antonio C.
  • Pelaez-Viña, Nazareth
  • Diaz-Pernalete, Rosa
  • Infante-Santos, Nazaret
  • Muñoz-Jurado, Ana
  • Porras-Pantojo, Manuel F.
  • Ibáñez-Costa, Alejandro
  • Luque, Raul M.
  • Solivera-Vela, Juan
Background: Intracerebral hemorrhages (ICHs) are prevalent, with high morbidity and mortality. We analyzed whether decompressive craniectomy (DC) without evacuation of the acute intraparenchymal hematoma could produce better functional outcomes than treatment with evacuation. Methods: Patients with acute ICH treated with DC without clot evacuation, or evacuation with or without associated craniectomy were included. Matched univariate analyses were performed, and a binary logistic regression model was constructed using the Glasgow Outcome Scale (GOS) and modified Rankin scale (mRS) as dependent variables. Results: 27 patients treated with DC without clot evacuation were compared to 36 patients with clot evacuation; eleven of the first group were matched with 18 patients with evacuation. A significantly better functional prognosis in the group treated with DC without clot evacuation was found. Patients aged < 55 years and treated with DC without clot evacuation had a significantly better functional prognosis (p = 0.008 and p = 0.039, respectively). In multivariate analysis, the intervention performed was the greatest predictor of functional status at the end of follow-up. Conclusions: DC without clot evacuation improves the functional prognosis of patients with acute intraparenchymal hematomas. Larger multicenter studies are warranted to determine whether a change in the management of acute ICH should be recommended., This work was funded by the Junta de Andalucía (BIO-0139), the Spanish Ministry of Science, Innovation and Universities (FPU16/05059), Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, "Investing in your future": PI16/00264; CD19/00255), MINECO (PID2019-105564RB-I00) and CIBERobn.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

  • Alors-Perez, Emilia
  • Blázquez-Encinas, Ricardo
  • Alcalá, Sonia
  • Viyuela-García, Cristina
  • Pedraza-Arévalo, Sergio
  • Herrero-Aguayo, Vicente
  • Jiménez-Vacas, Juan M.
  • Mafficini, Andrea
  • Sánchez-Frías, Marina E.
  • Cano, María T.
  • Abollo-Jiménez, Fernando
  • Marín-Sanz, Juan A.
  • Cabezas-Sainz, Pablo
  • Lawlor, Rita T.
  • Luchini, Claudio
  • Sánchez, Laura
  • Sánchez-Hidalgo, Juan M.
  • Ventura, Sebastián
  • Martin-Hijano, Laura
  • Gahete, Manuel D.
  • Scarpa, Aldo
  • Arjona-Sánchez, Álvaro
  • Ibáñez-Costa, Alejandro
  • Sainz, Bruno Jr.
  • Luque, Raúl M.
  • Castaño, Justo P.
© The Author(s) 2021., [Background]: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, requiring novel treatments to target both cancer cells and cancer stem cells (CSCs). Altered splicing is emerging as both a novel cancer hallmark and an attractive therapeutic target. The core splicing factor SF3B1 is heavily altered in cancer and can be inhibited by Pladienolide-B, but its actionability in PDAC is unknown. We explored the presence and role of SF3B1 in PDAC and interrogated its potential as an actionable target. [Methods]: SF3B1 was analyzed in PDAC tissues, an RNA-seq dataset, and publicly available databases, examining associations with splicing alterations and key features/genes. Functional assays in PDAC cell lines and PDX-derived CSCs served to test Pladienolide-B treatment effects in vitro, and in vivo in zebrafish and mice. [Results]: SF3B1 was overexpressed in human PDAC and associated with tumor grade and lymph-node involvement. SF3B1 levels closely associated with distinct splicing event profiles and expression of key PDAC players (KRAS, TP53). In PDAC cells, Pladienolide-B increased apoptosis and decreased multiple tumor-related features, including cell proliferation, migration, and colony/sphere formation, altering AKT and JNK signaling, and favoring proapoptotic splicing variants (BCL-XS/BCL-XL, KRASa/KRAS, Δ133TP53/TP53). Importantly, Pladienolide-B similarly impaired CSCs, reducing their stemness capacity and increasing their sensitivity to chemotherapy. Pladienolide-B also reduced PDAC/CSCs xenograft tumor growth in vivo in zebrafish and in mice. [Conclusion]. SF3B1 overexpression represents a therapeutic vulnerability in PDAC, as altered splicing can be targeted with Pladienolide-B both in cancer cells and CSCs, paving the way for novel therapies for this lethal cancer., This work has been supported by Spanish Ministry of Economy [MINECO; BFU2016–80360-R (to JPC)] and Ministry of Science and Innovation [MICINN; PID2019-105201RB-I00 (to JPC), PID2019-105564RB-I00 (to RML)]. Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, “Investing in your future”) [FIS Grants PI17/02287 and PI20/01301 (to MDG), PI18/00757 (to BS,Jr); DTS Grant DTS20/00050 (to RML)); Postdoctoral Grant Sara Borrell CD19/00255 (to AIC); Predoctoral contract FI17/00282 (to EAP)]. Coordinated grant (GC16173694BARB) from the Fundación Asociación Española Contra el Cáncer (AECC) (to BS,Jr). Spanish Ministry of Universities [Predoctoral contracts FPU14/04290 (to SPA); FPU16/06190 (to VHA); FPU18/02275 (to RBE)]. Boehringer Ingelheim Fonds travel grant (EAP). Junta de Andalucía (BIO0139). GETNE2016 and GETNE2019 Research grants (to JPC); and CIBERobn. Associazione Italiana Ricerca Cancro (AIRC 5×1000 n. 12182); Fondazione Italiana Malattie Pancreas – Ministero Salute [FIMPCUP_J38D19000690001]; Fondazione Cariverona: Oncology Biobank Project “Antonio Schiavi” (prot.203885/2017).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors

  • Pedraza-Arévalo, Sergio
  • Ibáñez-Costa, Alejandro
  • Blázquez-Encinas, Ricardo
  • Branco, Miguel R.
  • Vázquez-Borrego, Mari C.
  • Herrera-Martínez, Aura D.
  • Venegas Moreno, Eva
  • Serrano-Blanch, Raquel
  • Arjona-Sánchez, Álvaro
  • Gálvez-Moreno, María Ángeles
  • Korbonits, Marta
  • Soto-Moreno, Alfonso
  • Gahete, Manuel D.
  • Charalambous, Marika
  • Luque, Raúl M.
  • Castaño, Justo P.
Somatostatin receptor subtype 5 (SST5 ) is an emerging biomarker and actionable target in pituitary (PitNETs) and pancreatic (PanNETs) neuroendocrine tumors. Transcriptional and epigenetic regulation of SSTR5 gene expression and mRNA biogenesis is poorly understood. Recently, an overlapping natural antisense transcript, SSTR5-AS1, potentially regulating SSTR5 expression, was identified. We aimed to elucidate whether epigenetic processes contribute to the regulation of SSTR5 expression in PitNETs (somatotropinomas) and PanNETs. We analyzed the SSTR5/SSTR5-AS1 human locus in silico to identify CpG islands. SSTR5 and SSTR5-AS1 expression was assessed by quantitative real-time PCR (qPCR) in 27 somatotropinomas, 11 normal pituitaries (NPs), and 15 PanNETs/paired adjacent (control) samples. We evaluated methylation grade in four CpG islands in the SSTR5/SSTR5-AS1 genes. Results revealed that SSTR5 and SSTR5-AS1 were directly correlated in NP, somatotropinoma, and PanNET samples. Interestingly, selected CpG islands were differentially methylated in somatotropinomas compared with NPs. In PanNETs cell lines, SSTR5-AS1 silencing downregulated SSTR5 expression, altered aggressiveness features, and influenced pasireotide response. These results provide evidence that SSTR5 expression in PitNETs and PanNETs can be epigenetically regulated by the SSTR5-AS1 antisense transcript and, indirectly, by DNA methylation, which may thereby impact tumor behavior and treatment response., This research was funded by Junta de Andalucía (BIO-0139, P20_00442; PEER-0048-2020); Spanish Ministry of Economy (BFU2016-80360-R), Ministry of Science and Innovation (PID2019-105201RB-I00, PID2019-105564RB-I00); and ISCIII (PI16-00264, CD19/00255), co-funded with EU funds from FEDER Program. People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under project WHRI-ACADEMY, REA grant agreement n° 608765; MECD (FPU14/04290, FPU18/02275); EMBO (short term fellowship 6802); GETNE G2019 Research Grant; Fundación Eugenio Rodriguez Pascual (FERP2019); project grants from the UK Medical Research Council (MR/R022836/1; MR/L002345/1); and CIBERobn; CIBER Fisiopatología de la Obesidad y Nutriciín is an initiative of Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrative Clinical, Radiological, and Molecular Analysis for Predicting Remission and Recurrence of Cushing Disease

  • Moreno-Moreno, Paloma
  • Ibáñez-Costa, Alejandro
  • Venegas Moreno, Eva
  • Fuentes-Fayos, Antonio C.
  • Alhambra-Expósito, María R.
  • Fajardo-Montañana, Carmen
  • García-Martínez, Araceli
  • Dios Fuentes, Elena
  • Vázquez-Borrego, Mari C.
  • Remón-Ruiz, Pablo
  • Cámara, Rosa
  • Lamas, Cristina
  • Padillo-Cuenca, José Carlos
  • Solivera, Juan
  • Cano González, David A.
  • Gahete, Manuel D.
  • Herrera-Martínez, Aura D.
  • Picó-Alfonso, Antonio Miguel
  • Soto-Moreno, Alfonso
  • Gálvez-Moreno, María Ángeles
  • Castaño, Justo P.
  • Luque, Raúl M.
[Context] Adrenocorticotropin (ACTH)-secreting pituitary tumors (ACTHomas) are associated with severe comorbidities and increased mortality. Current treatments mainly focus on remission and prevention of persistent disease and recurrence. However, there are still no useful biomarkers to accurately predict the clinical outcome after surgery, long-term remission, or disease relapse., [Objectives] This work aimed to identify clinical, biochemical, and molecular markers for predicting long-term clinical outcome and remission in ACTHomas., [Methods] A retrospective multicenter study was performed with 60 ACTHomas patients diagnosed between 2004 and 2018 with at least 2 years’ follow-up. Clinical/biochemical variables were evaluated yearly. Molecular expression profile of the somatostatin/ghrelin/dopamine regulatory systems components and of key pituitary factors and proliferation markers were evaluated in tumor samples after the first surgery., [Results] Clinical variables including tumor size, time until diagnosis/first surgery, serum prolactin, and postsurgery cortisol levels were associated with tumor remission and relapsed disease. The molecular markers analyzed were distinctly expressed in ACTHomas, with some components (ie, SSTR1, CRHR1, and MKI67) showing instructive associations with recurrence and/or remission. Notably, an integrative model including selected clinical variables (tumor size/postsurgery serum cortisol), and molecular markers (SSTR1/CRHR1) can accurately predict the clinical evolution and remission of patients with ACTHomas, generating a receiver operating characteristic curve with an area under the curve of 1 (P < .001)., [Conclusion] This study demonstrates that the combination of a set of clinical and molecular biomarkers in ACTHomas is able to accurately predict the clinical evolution and remission of patients. Consequently, the postsurgery molecular profile represents a valuable tool for clinical evaluation and follow-up of patients with ACTHomas., This work was supported by the Junta de Andalucía (Nos. P20_00442, PEER-0048-2020, A-0006-2017, A-0055-2018, C-0015-2014, RC-0006-2018; postdoctoral grant DOC_01584, and BIO-0139); Ministry of Science and Innovation (Nos. PID2019-105564RB-I00 and PID2019-105201RB-I00); Instituto de Salud Carlos III, cofunded by the European Union (ERDF/ESF, “Investing in your future”; Nos. PI13/02043; PI16/00175, PI21/01012, and Sara Borrell programme CD19/00255); Spanish Ministry of Universities (predoctoral contract FPU16-05059); a GETNE2019 research grant; and CIBERobn. CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential

  • Alors-Perez, Emilia
  • Pedraza-Arévalo, Sergio
  • Blázquez-Encinas, Ricardo
  • Moreno-Montilla, María Trinidad
  • García-Vioque, Víctor
  • Berbel, Inmaculada
  • Luque, Raúl M.
  • Sainz, Bruno Jr.
  • Ibáñez-Costa, Alejandro
  • Castaño, Justo P.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers worldwide, mainly due to its late diagnosis and lack of effective therapies, translating into a low 5-year 12% survival rate, despite extensive clinical efforts to improve outcomes. International cooperative studies have provided informative multiomic landscapes of PDAC, but translation of these discoveries into clinical advances are lagging. Likewise, early diagnosis biomarkers and new therapeutic tools are sorely needed to tackle this cancer. The study of poorly explored molecular processes, such as splicing, can provide new tools in this regard. Alternative splicing of pre-RNA allows the generation of multiple RNA variants from a single gene and thereby contributes to fundamental biological processes by finely tuning gene expression. However, alterations in alternative splicing are linked to many diseases, and particularly to cancer, where it can contribute to tumor initiation, progression, metastasis and drug resistance. Splicing defects are increasingly being associated with PDAC, including both mutations or dysregulation of components of the splicing machinery and associated factors, and altered expression of specific relevant gene variants. Such disruptions can be a key element enhancing pancreatic tumor progression or metastasis, while they can also provide suitable tools to identify potential candidate biomarkers and discover new actionable targets. In this review, we aimed to summarize the current information about dysregulation of splicing-related elements and aberrant splicing isoforms in PDAC, and to describe their relationship with the development, progression and/or aggressiveness of this dismal cancer, as well as their potential as therapeutic tools and targets., This work has been supported by Spanish Ministry of Economy [MINECO; BFU2016-80360-R (to JPC)] and Ministry of Science and Innovation [MICINN; PID2019-105201RB-I00 (to JPC), PID2019-105564RB-I00 (to RML)]. Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, “Investing in your future”) [FIS DTS Grant DTS20/00050 (to RML)); Postdoctoral Grant Sara Borrell CD19/00255 (to AIC); Predoctoral contract FI17/00282 (to EAP)]. Spanish Ministry of Universities [FPU20/03958 (to VGV); FPU18/02275 (to RBE); postdoctoral contract under the program María Zambrano funded by the European Union Next Generation-EU (to SPA)]. Asociación Cáncer de Páncreas and AESPANC 2022 (to JPC); Boehringer Ingelheim Fonds travel grant (EAP). Junta de Andalucía (BIO-0139). GETNE2016 and GETNE2019 Research grants (to JPC); and CIBERobn. Part of this work was supported by COST (European Cooperation in Science and Technology – www.cost.eu) through the COST Action TRANSPAN (CA21116)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features

  • Flores-Martínez, Alvaro
  • Venegas Moreno, Eva
  • Dios Fuentes, Elena
  • Remón-Ruiz, Pablo
  • Gros Herguido, Noelia
  • Vázquez-Borrego, Mari C.
  • Madrazo Atutxa, Ainara
  • Japón, Miguel A.
  • Kaen, Ariel
  • Cárdenas Ruiz-Valdepeñas, Eugenio
  • Roldán, Florinda
  • Castaño, Justo P.
  • Luque, Raúl M.
  • Cano González, David A.
  • Soto-Moreno, Alfonso
The primary treatment for non-functioning pituitary tumors (NFPTs) is surgery, but it is often unsuccessful. Previous studies have reported that NFPTs express receptors for somatostatin (SST1-5) and dopamine (DRDs) providing a rationale for the use of dopamine agonists and somatostatin analogues. Here, we systematically assessed SST1-5 and DRDs expression by real-time quantitative PCR (RT-qPCR) in a large group of patients with NFPTs (n = 113) and analyzed their potential association with clinical and molecular aggressiveness features. SST1-5 expression was also evaluated by immunohistochemistry. SST3 was the predominant SST subtype detected, followed by SST2, SST5, and SST1. DRD2 was the dominant DRD subtype, followed by DRD4, DRD5, and DRD1. A substantial proportion of NFPTs displayed marked expression of SST2 and SST5. No major association between SSTs and DRDs expression and clinical and molecular aggressiveness features was observed in NFPTs., This work was supported by grants from the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación co-funded with Fondos FEDER (PI16/00175 to A.S.-M. and D.A.C; PI16/00264 to R.M.L.), the Sistema Andaluz de Salud (A-0006-2017 and A-0055-2018 to A.S.-M, C-0015-2014 and RC-0006-2018 to D.A.C.), Ministerio de Ciencia, Innovación (BFU2016-80360-R to J.P.C.; PID2019-105564RB-I00 to R.M.L.) and Junta de Andalucía (BIO-0139 to J.P.C. and R.M.L.), and CIBERobn. CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain. Part of the analyses included in this study was carried out within the REMAH (‘Spanish molecular registry of pituitary adenomas’) project, supported by Novartis Oncology as well as by the Andalusian and Spanish Societies of Endocrinology and Nutrition (SAEDYN and SEEN, respectively)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes

  • Jiménez-Vacas, Juan M.
  • Montero-Hidalgo, Antonio J.
  • Gómez-Gómez, Enrique
  • Sáez-Martínez, Prudencio
  • Fuentes-Fayos, Antonio C.
  • Closa, Adrià
  • González-Serrano, Teresa
  • Martínez-López, Ana
  • Sánchez-Sánchez, Rafael
  • López-Casas, Pedro P.
  • Sarmento-Cabral, André
  • Olmos, David
  • Eyras Jiménez, Eduardo
  • Castaño, Justo P.
  • Gahete, Manuel D.
  • Luque, Raul M.
Prostate cancer (PCa) is one of the leading causes of cancer-related deaths among men. Consequently, the identification of novel molecular targets for treatment is urgently needed to improve patients' outcomes. Our group recently reported that some elements of the cellular machinery controlling alternative-splicing might be useful as potential novel therapeutic tools against advanced PCa. However, the presence and functional role of RBM22, a key spliceosome component, in PCa remains unknown. Therefore, RBM22 levels were firstly interrogated in 3 human cohorts and 2 preclinical mouse models (TRAMP/Pbsn-Myc). Results were validated in in silico using 2 additional cohorts. Then, functional effects in response to RBM22 overexpression (proliferation, migration, tumorspheres/colonies formation) were tested in PCa models in vitro (LNCaP, 22Rv1, and PC-3 cell-lines) and in vivo (xenograft). High throughput methods (ie, RNA-seq, nCounter PanCancer Pathways Panel) were performed in RBM22 overexpressing cells and xenograft tumors. We found that RBM22 levels were down-regulated (mRNA and protein) in PCa samples, and were inversely associated with key clinical aggressiveness features. Consistently, a gradual reduction of RBM22 from non-tumor to poorly differentiated PCa samples was observed in transgenic models (TRAMP/Pbsn-Myc). Notably, RBM22 overexpression decreased aggressiveness features in vitro, and in vivo. These actions were associated with the splicing dysregulation of numerous genes and to the downregulation of critical upstream regulators of cell-cycle (i.e., CDK1/CCND1/EPAS1). Altogether, our data demonstrate that RBM22 plays a critical pathophysiological role in PCa and invites to suggest that targeting negative regulators of RBM22 expression/activity could represent a novel therapeutic strategy to tackle this disease., This research was funded by the Spanish Ministry of Science, Innovation, and Universities (Research‐Grant: PID2019‐105564RB‐I00; Predoctoral contracts: FPU16/05059, FPU17/00263, FPU18/02485), Health Institute Carlos III (DTS20-00050), Junta de Andalucia [BIO-0139; Consejería de Transformación Económica, Industria, Conocimiento y Universidades (P20_00442); Consejería de Salud y Familias, co-funded by European Union (Programa Operativo FEDER de Andalucía 2014-2020, “Andalucía se mueve con Europa”: PEER-0048-2020)], and CIBERobn (CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain). Funding for open access charge: University of Córdoba/CBUA. Some images were taken from Servier Medical Art (smart.servier.com) under the Creative Commons Attribution 3.0 Unported License. Special thanks to the staff of Biobank of the IMIBIC and of the experimental animal service (SAE) of the UCO/IMIBIC. We are gratefully indented to all the patients and their families for generously donating the samples and clinical data for research purposes. All authors have read the journal's authorship agreement.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Decompressive hemicraniectomy without evacuation of acute intraparenchymal hemorrhage

  • Blanco-Acevedo, Cristóbal
  • Aguera-Morales, Eduardo
  • Fuentes-Fayos, Antonio C.
  • Pelaez-Viña, Nazareth
  • Diaz-Pernalete, Rosa
  • Infante-Santos, Nazaret
  • Muñoz-Jurado, Ana
  • Porras-Pantojo, Manuel F.
  • Ibáñez-Costa, Alejandro
  • Luque, Raul M.
  • Solivera-Vela, Juan
Background: Intracerebral hemorrhages (ICHs) are prevalent, with high morbidity and mortality. We analyzed whether decompressive craniectomy (DC) without evacuation of the acute intraparenchymal hematoma could produce better functional outcomes than treatment with evacuation. Methods: Patients with acute ICH treated with DC without clot evacuation, or evacuation with or without associated craniectomy were included. Matched univariate analyses were performed, and a binary logistic regression model was constructed using the Glasgow Outcome Scale (GOS) and modified Rankin scale (mRS) as dependent variables. Results: 27 patients treated with DC without clot evacuation were compared to 36 patients with clot evacuation; eleven of the first group were matched with 18 patients with evacuation. A significantly better functional prognosis in the group treated with DC without clot evacuation was found. Patients aged < 55 years and treated with DC without clot evacuation had a significantly better functional prognosis (p = 0.008 and p = 0.039, respectively). In multivariate analysis, the intervention performed was the greatest predictor of functional status at the end of follow-up. Conclusions: DC without clot evacuation improves the functional prognosis of patients with acute intraparenchymal hematomas. Larger multicenter studies are warranted to determine whether a change in the management of acute ICH should be recommended., This work was funded by the Junta de Andalucía (BIO-0139), the Spanish Ministry of Science, Innovation and Universities (FPU16/05059), Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, "Investing in your future": PI16/00264; CD19/00255), MINECO (PID2019-105564RB-I00) and CIBERobn.